VIDEO: Mogamulizumab ‘promising’ therapy for patients with rare ATL
A humanized monoclonal antibody directed against C-C chemokine receptor 4 effectively treated patients with adult T-cell leukemia/lymphoma when compared with standard chemotherapy, according to research Adrienne A. Phillips, MD, MPH, of Weill Cornell Medicine and NewYork-Presbyterian, presented at the ASCO Annual Meeting.
Phillips and colleagues conducted a randomized study in which patients either received mogamulizumab (Poteligeo, Kyowa Kirin Pharmaceutical Development) or a standard chemotherapy treatment of either pralatrexate (Folotyn, Spectrum Pharmaceuticals), DHAP or gemcitabine-oxaliplatin.
The response rate in patients who received mogamulizumab was 34% compared with no response in patients who received chemotherapy.
“Mogamulizumab... is promising for patients with ATL who otherwise have had no standard options [in the U.S.], Phillips said. “[Also], chemotherapy in the relapsed refractory setting is ineffective.”